Innoviva Cash Flow from Financial Activities 2010-2024 | INVA
Innoviva cash flow from financial activities from 2010 to 2024. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
Innoviva Annual Cash Flow Financial
(Millions of US $) |
| 2024 |
$-13 |
| 2023 |
$-172 |
| 2022 |
$-56 |
| 2021 |
$-452 |
| 2020 |
$-30 |
| 2019 |
$-24 |
| 2018 |
$-238 |
| 2017 |
$-163 |
| 2016 |
$-98 |
| 2015 |
$-107 |
| 2014 |
$149 |
| 2013 |
$398 |
| 2012 |
$236 |
| 2011 |
$26 |
| 2010 |
$231 |
| 2009 |
$12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.175B |
$0.359B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
